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medication of all patients and 1 hour after that echocardiograpdic
parameters was measured again, and the results were compared.
RESULTS: Peak pulmonary artery pressure and pulmonary accel-
eration time (PAT) signiﬁcantly improved 1 hour after 100 mgoral
single dose of Sildenaﬁl (p < 0.005, 95% CI 5.41–22.93 and
p = 0.005 95% CI -12.89–2.95 respectively). In addition
although the right heart dimensions (right atrium & ventricle)
showed a trend toward improvement, but were not statistically
signiﬁcant (p = 0.135, p = 0.08 respectively). CONCLUSION:
These results suggest that Sildenaﬁl has a acute signiﬁcant
improvement effect on PAP and PAT in patients with PPH.
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RESULTS FROMTHE MOTIVTRIAL
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OBJECTIVES: Community Acquired Pneumonia (CAP) is a
leading cause of hospitalisation and mortality in industrialised
countries. This study was an economic evaluation comparing
moxiﬂoxacin with a combination of levoﬂoxacin plus ceftriaxone
in patients hospitalised with CAP in Germany. METHODS: The
MOTIV trial was a multinational, prospective, randomized,
double-blind study in adults with CAP requiring hospitalisation
and parenteral antibiotic therapy. Patients were randomised to
either moxiﬂoxacin (N = 368), or levoﬂoxacin plus ceftriaxone
(N = 365) and received sequential treatment with intravenous
followed by oral antibiotics for 7–14 days. The primary effective-
ness endpoint was clinical response 5–7 days after completion of
treatment. Resource use recorded included length of stay, ward
type, investigations and procedures performed and dose and
frequency of study drug used. Costs were calculated from a
German hospital perspective, drug costs were taken from the Rote
Liste and other costs from a recent publication. A stochastic
sensitivity analysis was performed. RESULTS: Mean age was 65
years (range 18–101) and 58% of patients had severe CAP. The
percentage of patients reporting clinical response (moxiﬂoxacin:
80%, comparator: 84%) met criteria for clinical equivalence so a
cost-minimisation analysis was performed. Mean per patient cost
was €2190 (95% CI: €1954, €2463) for the moxiﬂoxacin group,
and €2619 (95% CI: €2422, €2832) for the comparator group,
difference (-€430, 95%CI: -€740, -€138).Medication costs were
signiﬁcantly lower for moxiﬂoxacin than comparator (-€470,
95% CI: -€522, -€421) but accounted for only 15–30% of total
costs. Subgroup analysis of patients with COPD, cardiovascular
disease, microbiologically proven pneumonia, or severe CAP at
baseline produced consistent ﬁndings. Average cost was sensitive
to price paid for study drugs and the daily cost of hospital stay.
CONCLUSION: Treatment with moxiﬂoxacin was signiﬁcantly
less costly than treatment with levoﬂoxacin plus ceftriaxone, with
no clinically signiﬁcant difference in outcomes achieved.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
is one of the most common chronic and disabling diseases
worldwide. The objectives of this study were to measure the
societal costs of COPD including both direct and indirect costs,
and to estimate the costs for different severity grades of disease
according to changed Swedish guidelines. METHODS: A well-
deﬁned and representative cohort of subjects was used to
examine the costs of COPD. Regular telephone interviews were
done with 212 subjects derived from the OLIN-Studies in
northern Sweden. The severity grades of COPD were divided
according to changed Swedish guidelines, and furthermore Mild
COPD (FEV1 50–79% of predicted) was divided into three
sub-groups, Mild I, II and III. RESULTS: A positive relation-
ship was found between costs and severity grades of COPD,
patients with lower FEV1 % of predicted normal being signiﬁ-
cantly more expensive. Furthermore, the total costs differed sig-
niﬁcantly between the Mild and Pre-clinical severity groups,
from a mean value of SEK 2,513 per subject in the Pre-clinical
group to SEK 28,463 for subjects having FEV1 50–59% of
predicted. The same pattern was found both in direct and indi-
rect costs. Costs for medicines and hospitalisations increased
signiﬁcantly according to FEV1 values in the Mild and Pre-
clinical groups of disease. Costs for disability pension among
indirect costs showed a similar trend. The annual total costs for
Severe (FEV1 < 30% of predicted), Moderate (30–49%), Mild I
(50–59%), Mild II (60–69%), Mild III (70–79%), and Pre-
clinical COPD (>79%) were SEK 183,474, 70,609, 28,463,
11,527, 6,287 and 2,513, respectively. CONCLUSION: Large
variations were found in both the level and breakdown of costs
for COPD, mainly depending on the severity of the disease.
When dividing mild COPD into three different severity grades
of disease, we also found a positive relationship between costs
and severity of disease.
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OBJECTIVES: Assessment of the inﬂuence of nicotine addic-
tion, time of duration and severity of COPD on the frequency of
exacerbations. METHODS: 71 patients with moderate-to-
severe COPD (30 with moderate and 41 with severe) were
enrolled to the study. The smoking status, FEV1 value, time of
duration of COPD, and a one-year history of incidence of exac-
erbations were assessed in all the subjects. The relationship
between the number of exacerbations and the studied features
was evaluated with the regression model. RESULTS: Thirteen
(18.3%) subjects were current smokers, 9 (12.7%) had never
smoked and 50 (70%) had smoked in the past. The mean inten-
sity of cigarette smoking amounted to 34.7 pack-years [CI:
28.7–40.7]. The mean time of COPD duration was 9.2
[CI: 7.7–10.8] years, the mean frequency of exacerbation—3.1
[CI: 2.5–3.6] per year, and the mean % value of FEV1 was
48.1% [CI: 43.7–52.5]. There was no signiﬁcant relationship
between the frequency of exacerbations and the number of
pack-years, smoking status, % value of FEV1 and severity of
COPD. A signiﬁcant correlation was observed between the time
of duration of COPD and average number of exacerbations
(r = 0.31, p = 0.009). It was calculated that each successive year
of COPD duration is associated with 3% accumulation of exac-
erbation risk (determination coefﬁcient—R2 = 0.03). CON-
CLUSION: Long-time duration of COPD is related to a
signiﬁcant increase of the risk of COPD exacerbations—the key
drivers in the overall costs of the disease.
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OBJECTIVES: The aim of the study was to estimate the eco-
nomic impact of improved pharmaceutical care in obstructive
airway diseases (OAD) by evaluating the effects of the introduc-
tion of new pharmaceutical treatments in the costs of OAD
treatment between 1996 and 2005. METHODS: To analyse the
real change in the costs of OAD treatment, we estimated costs in
2005 assuming that the treatment practices (pharmaceuticals,
hospitalizations, outpatient visits) had been similar to 1996 and
subsequently compared these expected costs to the actual costs in
2005. The change in real costs due to improved pharmaceutical
care was estimated by evaluating the change in the number of
exacerbations requiring treatment. A spreadsheet based probabi-
listic simulation model was used. The data on health care
resources, pharmaceuticals and costs were obtained from
national registries. The effectiveness of pharmaceutical treat-
ments in reducing exacerbations was obtained from three
published meta-analyses. RESULTS: Compared to 1996, the
improved pharmaceutical treatment decreased other OAD treat-
ment costs in 2005 by 33.7 (95% CI: 19.4–50.9) million euros
explaining 42.1% of the decrease in secondary health care costs
of OAD in Finland. When adjusting for the increase in the
number of patients, the extra costs of new pharmaceutical treat-
ments were 5.1 million euros. Thus the increase in pharmaceu-
tical costs was offset more than 6-fold by the reduction in the
secondary health care costs. CONCLUSION: The OAD treat-
ment costs in Finland have decreased signiﬁcantly as a result of
increased use of more effective pharmaceuticals. When pharma-
ceuticals are properly evaluated as one part of the treatment
process, the expressed concerns over the increasing pharmaceu-
tical costs seem to be unfounded in the case of OAD.
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OBJECTIVES: To describe health care provision and resource
consumption in patients with pulmonary arterial hypertension
(PAH) in Germany. METHODS: A multi-centre, cross-sectional,
retrospective and prospective study was conducted which
addressed PAH care in hospitals and in the ambulant setting
taking into account the patients’ perspective. Study period
covered 15 months. In hospitals, chart abstraction was accom-
plished 12 months retrospectively and 3 months prospectively. A
GPs’ questionnaire covered health care utilisation in the ofﬁce-
based sector and two patient questionnaires were applied to
collect data on health status, resource consumption (over 3
months), and quality of life. RESULTS: Ten hospitals enrolled
150 patients with PAH; data of 118 patients (treated October
2004-December 2006) were considered within this interim analy-
sis. Response rate of GP questionnaire was 52%, of patient
questionnaires 85% (1st questionnaire) and 76% (2nd question-
naire). Mean age of patients was 55 years (SD 14), 72% were
female. 60% suffered from idiopathic PAH and 40% from PAH
mainly associated with collagen vascular diseases (37%), con-
genital systemic-to-pulmonary shunts (26%), or portal hyperten-
sion (22%). Mean duration from occurrence of ﬁrst symptoms
until diagnosis was 2.3 years (SD 4.4). Within 15 months mean
number of GP visits was 23.1 (SD 16.2); mean number of
hospital visits was 4.5. 44% of patients were hospitalised
(mean length of stay: 7.1 days SD 6.1). Hospitalisation
with surgical interventions (5% of hospital stays) occurred
for port-transplantation or catheter replacement. 59% of
patients received anticoagulants, 60% diuretics, 27% calcium-
antagonists, 66% endothelin-receptor antagonists, 20% inhala-
tive prostacyclin analogues, and 25% PDE5 inhibitors. 10% of
patients participated in rehabilitation with a mean length of stay
of 30.1 days (SD 11.3). CONCLUSION: This analysis is the ﬁrst
step in a comprehensive study on health care provision and
economic burden of PAH in Germany. In a second step outcomes,
e.g. disease severity and quality of life, will be assessed.
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COST GROUPS, RXGROUPS,AND PRIOR COST FORTEXAS
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OBJECTIVES: The objective of this study was to test the ability
of Diagnostic Cost Groups (DCGs), RxGroups, and prior cost
risk models to identify high risk patients within the Texas
Medicaid Chronic Obstructive Pulmonary Disease (COPD)
population who could beneﬁt from case management interven-
tion. METHODS: DCGs, RxGroups, and prior cost risk models
were used to predict future medical costs. ICD-9 diagnostic
codes, NDC drug codes and 2001 total health care costs were
input into the risk models. The study included Texas Medicaid
patients under the age of 65 who had an inpatient diagnoses of
COPD in 2000 and were continuously enrolled in Medicaid from
2000–2002 (n = 7967). The risk models predicted total health
care costs for 2002. Predicted costs were compared to actual
2002 costs using R2 and mean absolute prediction error. Predic-
tion of high cost cases were analyzed using the positive predictive
value (PPV) of the top 5% of high cost patients. RESULTS: The
R2 was 0.035 for the DCG inpatient + RxGroups model and
0.033 for the prior cost model. For the top 5% of high cost
patients the DCG + RxGroups model had a PPV of 20.5% (82/
399). PPV for the prior cost model was 33.1%(132/399). The
mean absolute prediction error was $7293 for the DCG
inpatient + RxGroups model and $7429 for the prior cost model.
CONCLUSION: Diagnosis-based risk adjustment models using
only inpatient and pharmacy data may not be as useful as prior
cost data when attempting to identify future high cost cases
among Texas Medicaid COPD patients. A combination of
diagnosis-based risk adjustment models and prior cost data may
prove to be the most effective way to identify COPD candidates
for case management.
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